Healthscope positioned for continued momentum

Scott Power


TPG and The Carlyle Group have sold A$810m, or 53% of their A$1.8bn stake in HSO (will retain a 17.8% holding). Our Investment view is the company has a solid track record of strong earnings growth of 13% over the last 4 years, along with stable, high CF generation and high cash conversion (98.5% over the last 4 years) on effective working capital management. We view the company as a core holding and well positioned for continued momentum, targeting mid double-digit earnings growth through FY18, operating margin uplift of 200bp on efficiency gains, continued strong cash conversion and a dividend payout ratio c70% (equating to a 2.5-3% yield). Healthscope (HSO, Add, Price Target A$3.22)

1 topic

1 stock mentioned

Scott Power
Scott Power
Senior Analyst

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Sign In or Join Free to comment